My take is this is seperate to the SubB2M program. EXO-NET is a platform technology used for isolating the relevant exosomes from the sample in question i.e., blood sample from a potential / suspected ovarian cancer patient. The assay UQ will be develop will to detect the relevant exosome marker in question.
Please also note that releasing news of signing a CRO for the SubB2M program is also no guarantee. Will they tech transfer a test developed in the iNOVIQ lab (ELISA / IHC) and if so, optimisation, validation and test readiness under a NATA / CAP accredited lab will need to be completed in roughly 12 - 18 months if we are to see an LDT launch in 2023. Importantly, are they manufacturing a research grade SubB2M product in the meantime in order to provide to the CRO to test in the developed assay?
Ann: INOVIQ & UQ Collaborate on Exosome-based Ovarian Cancer Test, page-19
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
48.0¢ |
Change
0.005(1.05%) |
Mkt cap ! $44.16M | |||
| Open | High | Low | Value | Volume |
| 48.0¢ | 48.0¢ | 46.5¢ | $27.21K | 57.07K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 48.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 50.0¢ | 10406 | 5 |
View Market Depth
| Last trade - 15.38pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
48.0¢ |
Change
0.005 ( 1.03 %) |
||||
| Open | High | Low | Volume | ||
| 47.0¢ | 48.0¢ | 46.5¢ | 14476 | ||
| Last updated 13.37pm 24/05/2024 ? | |||||
| IIQ (ASX) Chart |